Evidence map›Paper›PMID 28074004›Full record

ArticleScience signaling2017

Signaling by two-component system noncognate partners promotes intrinsic tolerance to polymyxin B in uropathogenic Escherichia coli.

Kirsten R Guckes, Erin J Breland, Ellisa W Zhang, Sarah C Hanks, Navleen K Gill, Holly M S Algood, Jonathan E Schmitz, Charles W Stratton, Maria Hadjifrangiskou

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Colistin resistance dynamics inAntimicrobial agents and chemotherapy · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Bacterial signaling as an antimicrobial target.Current opinion in microbiology · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kirsten R GuckesDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Erin J BrelandDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Ellisa W ZhangDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sarah C HanksBarnard College, New York, NY 10027, USA.
Navleen K GillVanderbilt University, Nashville, TN 37240, USA.
Holly M S AlgoodDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jonathan E SchmitzDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Charles W StrattonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Maria HadjifrangiskouDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. maria.hadjifrangiskou@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · USBarnard College · US

Funding

University of Michigan Training Program in Genomic ScienceT32HG000040 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sebastian Zoellner · 1995 to 2026
$16.4M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Two-component system interactions as uropathogenic Escherichia coli drug targetsR01AI107052 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HADJIFRANGISKOU, MARIA · 2015 to 2019
$1.9M
NHGRI NIH HHS T32 HG000040NIAID NIH HHS R01 AI107052NIGMS NIH HHS T32 GM007628
6 · The paper itself

Abstract

Bacteria use two-component systems (TCSs) to react appropriately to environmental stimuli. Typical TCSs comprise a sensor histidine kinase that acts as a receptor coupled to a partner response regulator that coordinates changes in bacterial behavior, often through its activity as a transcriptional regulator. TCS interactions are typically confined to cognate pairs of histidine kinases and response regulators. We describe two distinct TCSs in uropathogenic Escherichia coli (UPEC) that interact to mediate a response to ferric iron. The PmrAB and QseBC TCSs were both required for proper transcriptional response to ferric iron. Ferric iron induced the histidine kinase PmrB to phosphotransfer to both its cognate response regulator PmrA and the noncognate response regulator QseB, leading to transcriptional responses coordinated by both regulators. Pretreatment of the UPEC strain UTI89 with ferric iron led to increased resistance to polymyxin B that required both PmrA and QseB. Similarly, pretreatment of several UPEC isolates with ferric iron increased tolerance to polymyxin B. This study defines physiologically relevant cross talk between TCSs in a bacterial pathogen and provides a potential mechanism for antibiotic resistance of some strains of UPEC.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug ToleranceEscherichia coli ProteinsFerric CompoundsGene Expression Regulation, BacterialIonsPolymyxin BProtein BindingReverse Transcriptase Polymerase Chain ReactionSignal TransductionTranscription FactorsUropathogenic Escherichia coliAnti-Bacterial AgentsBacterial ProteinsEscherichia coli ProteinsFerric CompoundsIonspmrA protein, BacteriaPmrB protein, bacteriaPolymyxin BQseB protein, E coliQseC protein, E coliTranscription Factors

Identifiers

PMID28074004
PMCPMC5677524
OpenAlexW2573553863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.